Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Reviewartikel, 2016
In 2014 the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (RAV) conducted a review and analysis of the state of knowledge on the duration of follow-up after exposure to human immunodeficiency virus (HIV). Up until then a follow-up of 12 weeks after exposure had been recommended, but improved tests and new information on early diagnosis motivated a re-evaluation of the national recommendations by experts representing infectious diseases and microbiology, county medical officers, the RAV, the Public Health Agency, and other national authorities. Based on the current state of knowledge the Public Health Agency of Sweden and the RAV recommend, starting in April 2015, a follow-up period of 6 weeks after possible HIV-1 exposure, if HIV testing is performed using laboratory-based combination tests detecting both HIV antibody and antigen. If point-of-care rapid HIV tests are used, a follow-up period of 8 weeks is recommended, because currently available rapid tests have insufficient sensitivity for detection of HIV-1 antigen. A follow-up period of 12 weeks is recommended after a possible exposure for HIV-2, since presently used assays do not include HIV-2 antigens and only limited information is available on the development of HIV antibodies during early HIV-2 infection. If pre- or post-exposure prophylaxis is administered, the follow-up period is recommended to begin after completion of prophylaxis. Even if infection cannot be reliably excluded before the end of the recommended follow-up period, HIV testing should be performed at first contact for persons who seek such testing.
hiv follow-up window period
prophylaxis
hiv-2
hiv-1
Författare
Hans Gaines
Karolinska Institutet
Folkhälsomyndigheten
Karolinska universitetssjukhuset
Jan Albert
Referensgruppen för AntiViral terapi (RAV)
Karolinska Institutet
Karolinska universitetssjukhuset
Maria Axelsson
Folkhälsomyndigheten
Torsten Berglund
Folkhälsomyndigheten
Magnus Gisslén
Referensgruppen för AntiViral terapi (RAV)
Göteborgs universitet
A. Sonnerborg
Karolinska universitetssjukhuset
Referensgruppen för AntiViral terapi (RAV)
Karolinska Institutet
Anders Blaxhult
Västmanlands sjukhus
Gordana Bogdanovic
Karolinska universitetssjukhuset
Maria Brytting
Folkhälsomyndigheten
Christina Carlander
Västmanlands sjukhus
Referensgruppen för AntiViral terapi (RAV)
Leo Flamholc
Referensgruppen för AntiViral terapi (RAV)
Skånes universitetssjukhus (SUS)
Per Follin
Västra Götalandsregionen
Axana Haggar
Socialstyrelsen
Per Hagstam
Skånes universitetssjukhus (SUS)
Marcus Johansson
Länssjukhuset i Kalmar
Lars Navér
Karolinska universitetssjukhuset
Karolinska Institutet
Referensgruppen för AntiViral terapi (RAV)
Jenny Persson Blom
Arbetsmiljöverket
Agneta Samuelson
Karolinska universitetssjukhuset
Helena Ström
Socialstyrelsen
Martina Sundqvist
Universitetssjukhuset Örebro
Veronica Svedhem Johansson
Karolinska universitetssjukhuset
Karin Tegmark Wisell
Folkhälsomyndigheten
Anders Tegnell
Folkhälsomyndigheten
Rigmor Thorstensson
Folkhälsomyndigheten
Infectious Diseases
2374-4235 (ISSN) 2374-4243 (eISSN)
Vol. 48 2 93-98Ämneskategorier
Infektionsmedicin
DOI
10.3109/23744235.2015.1089593
PubMed
26414596